 | | Vol. 16.09 – 7 March, 2024 |
| |
|
|
| Functional metabolic analysis revealed that lipid droplets together with peroxisomes, which researchers showed to be enriched and active in the long-term estrogen-deprived cells, controlled redox homeostasis and conferred metabolic adaptability to the resistant tumors.
[Science Translational Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Gradient rotating magnetic field exposure had a notable impact on the F-actin arrangement of MDA-MB-231, BT-549, and MDA-MB-468 cells, inhibiting cell migration and invasion.
[Research] |
|
|
|
| Scientists demonstrated that eEF1A2 exhibited oncogenic or tumor-suppressor functions depending on its interaction with METTL13 or the phosphatase PTEN, respectively.
[Science Signaling] |
|
|
|
| LINC00460 was demonstrated to promote stem cell-like and epithelial-mesenchymal transition characteristics in breast cancer cells.
[Oncogene] |
|
|
|
| Researchers investigated whether the effects of a drug combination on tumor size was reflected in changes in tumor metabolism using glucose labeling in a TNBC xenograft model.
[Biomedicine & Pharmacotherapy] |
|
|
|
| The authors described palazestrant, a novel, orally bioavailable complete estrogen receptor (ER) antagonist and selective ER degrader. Palazestrant, like fulvestrant, had no agonist activity on the ER and completely blocked estrogen-induced transcriptional activity.
[Molecular Cancer Therapeutics] |
|
|
|
| Using reverse transcription‑quantitative PCR and western blotting, investigators discovered that kinesin family member 20B (KIF20B) mRNA and protein expression levels were upregulated in most breast cancer cell lines but were scarcely expressed in normal mammary epithelial cells.
[International Journal of Oncology] |
|
|
|
|
| The authors summarize the interaction mechanisms and biological significance of N6-methyladenosine (m6A) modifications and non-coding RNAs in breast cancer, focusing on the clinical application value of m6A modification in breast cancer diagnosis and prognosis.
[International Journal Of Cancer] |
|
|
|
|
| The National Cancer Institute awarded a $143,000 grant to Dr. Mahavir Bhupal Chougule, associate professor of pharmaceutical sciences, to develop first-in-class medicines that will block the function of human epidermal growth factor receptor 2 in this form of breast cancer.
[Mercer University] |
|
|
|
| Cancer Grand Challenges announced funding for five new global research teams to take on some of the toughest cancer challenges. Team SAMBAI is one of the five organizations that will receive up to $25 million over five years and will unite interdisciplinary researchers worldwide to drive progress in cancer research.
[Cancer Grand Challenges (Business Wire)] |
|
|
|
|
| April 24 – 26, 2024
Vienna, Austria |
|
|
|
|
|
| | Princess Margaret Cancer Centre – Toronto, Ontario, Canada |
|
|
|
| | Montreal Clinical Research Institute РMontr̩al, Qu̩bec, Canada |
|
|
|
| | Augusta University – Augusta, Georgia, United States |
|
|
|
| | UC Davis – Davis, California, United States |
|
|
|
| | Cyprus Cancer Research Institute – Aglandjia, Cyprus |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
